Slingshot members are tracking this event:
Bluebird Bio (BLUE) to complete Phase 1/2 study of LentiGlobin BB305 to subjects with beta-thalassemia major or severe sickle cell disease in December 2017
Slingshot Insights Explained
Dec 10, 2017
Don’t see a project related to the catalyst you care about?
Related Keywords Phase 1/2 Study, Lentiglobin, Lentiglobin Bb305, Beta-thalassemia, Sickle Cell Disease